Sipione S, Eshpeter A, Lyon J G, Korbutt G S, Bleackley R C
Department of Biochemistry, 460 Medical Sciences Building, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
Department of Surgery, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.
Diabetologia. 2004 Mar;47(3):499-508. doi: 10.1007/s00125-004-1349-z. Epub 2004 Feb 14.
AIM/HYPOTHESIS: Embryonic stem (ES) cells have been proposed as a potential source of tissue for transplantation for the treatment of Type 1 diabetes. However, studies showing differentiation of beta cells from ES cells are controversial. The aim of this study was to characterise the insulin-expressing cells differentiated in vitro from ES cells and to assess their suitability for the treatment of diabetes.
ES cell-derived insulin-expressing cells were characterised by means of immunocytochemistry, RT-PCR and functional analyses. Activation of the Insulin I promoter during ES-cell differentiation was assessed in ES-cell lines transfected with a reporter gene. ES cell-derived cultures were transplanted into STZ-treated SCID-beige mice and blood glucose concentrations of diabetic mice were monitored for 3 weeks.
Insulin-stained cells differentiated from ES cells were devoid of typical beta-cell granules, rarely showed immunoreactivity for C-peptide and were mostly apoptotic. The main producers of proinsulin/insulin in these cultures were neurons and neuronal precursors and a reporter gene under the control of the insulin I promoter was activated in cells with a neuronal phenotype. Insulin was released into the incubation medium but the secretion was not glucose-dependent. When the cultures were transplanted in diabetic mice they formed teratomas and did not reverse the hyperglycaemic state.
CONCLUSIONS/INTERPRETATION: Our studies show that insulin-positive cells in vitro-differentiated from ES cells are not beta cells and suggest that alternative protocols, based on enrichment of ES cell-derived cultures with cells of the endodermal lineage, should be developed to generate true beta cells for the treatment of diabetes.
目的/假设:胚胎干细胞(ES细胞)已被提议作为移植组织的潜在来源,用于治疗1型糖尿病。然而,关于ES细胞分化为β细胞的研究存在争议。本研究的目的是鉴定从ES细胞体外分化出的胰岛素表达细胞,并评估它们在糖尿病治疗中的适用性。
通过免疫细胞化学、逆转录聚合酶链反应(RT-PCR)和功能分析对ES细胞来源的胰岛素表达细胞进行鉴定。在用报告基因转染的ES细胞系中评估ES细胞分化过程中胰岛素I启动子的激活情况。将ES细胞来源的培养物移植到经链脲佐菌素(STZ)处理的SCID-米色小鼠体内,并监测糖尿病小鼠的血糖浓度3周。
从ES细胞分化出的胰岛素染色细胞缺乏典型的β细胞颗粒,很少显示C肽免疫反应性,且大多凋亡。这些培养物中胰岛素原/胰岛素的主要产生者是神经元和神经前体细胞,并且在具有神经元表型的细胞中,胰岛素I启动子控制下的报告基因被激活。胰岛素释放到孵育培养基中,但分泌不依赖葡萄糖。当将这些培养物移植到糖尿病小鼠体内时,它们形成了畸胎瘤,并未逆转高血糖状态。
结论/解读:我们的研究表明,从ES细胞体外分化出的胰岛素阳性细胞不是β细胞,并建议应开发基于用内胚层谱系细胞富集ES细胞来源培养物的替代方案,以生成用于治疗糖尿病的真正β细胞。